key: cord-0922990-yv3av15i
authors: Walker, Karrie
title: SARS-CoV-2 Vaccine
date: 2020-09-02
journal: Glob Reprod Health
DOI: 10.1097/grh.0000000000000042
sha: 33a2c95c187ddd500546489b267ceb9b5781f119
doc_id: 922990
cord_uid: yv3av15i

With the SARS-CoV-2 pandemic creating such a wide-reaching health crisis, it is imperative that a safe and effective vaccine be developed promptly for global availability. As such, there are several vaccine development projects currently underway aiming to meet this critical demand. However, COVID vaccine development is not immune to the inherent limitations and challenges that are encountered during vaccine clinical trials.

Unlike the SARS-CoV-1 epidemic in 2003, which largely remained local and quickly vanished from the circulation, SARS-CoV-2 succeeded in rapidly spreading globally [1] . As a result, we are facing a worldwide COVID pandemic. There is virtually no corner of the world that this highly infectious virus has not touched and there is no certainty regarding when or whether this pandemic will Table 1 Different vaccine platforms currently being investigated for SARS-CoV-2 and their benefits/limitations [2, 3] . ' Brief Report end. With this wide-reaching health crisis, there is an unprecedented need for development of a safe and effective vaccine that can be made globally available [2] . There are 2 primary goals in a development of a vaccine: (1) protection from infection due to seroconversion and (2) prevention of clinically symptomatic disease (especially amelioration of severe disease that requires high intensity medical care and taxes the medical system) [2] . If a vaccine succeeds in hitting these 2 aims, then we will see a reduced population transmissibility and prevention of secondary epidemics or pandemics.

Normally, 12-18 months is required to develop a new vaccine (development, clinical trials, and regulatory approval) [1] . To date, upwards of ninety different vaccines are undergoing development from groups around the world to fight SARS-CoV-2. At least 6 of these groups have started to test the safety and efficacy in human volunteers [3] . Many vaccine platforms are being utilized in this global effort, which all have unique advantages and limitations ( Table 1) . Overall, vaccine characteristics that are needed include: speed and flexibility of manufacturing, safety and reactogenicity, production of humoral and cellular immunogenicity, durability of immunity, appropriate scale and cost of manufacturing, vaccine stability and cold chain requirements [2] . While this swift movement with maximal globally-involved efforts toward vaccine development is encouraging, there are still many challenges to face before a vaccine can be made widely available ( Table 2) .

An evidence based perspective on mRNA-SARS-CoV-2 vaccine development

A strategic approach to COVID-19 vaccine R&D

The race for coronavirus vaccines: a graphical guide

Table 2 Possible hurtles/limitations to clinical trials creating a vaccine

The author declares that there is no financial conflict of interest with regard to the content of this report.

Example: Vaccine-associated enhanced respiratory diseaseNo in vivo data on type or level of immunity required to protect from subsequent reinfection and duration of that protection Trial needs prolonged follow-up of initial vaccine cohort to determine durability of immunity Need for testing parameters to distinguish immune response from prior vaccine versus infectionHigh mutation rate of single-stranded RNA virus such as SARS-CoV-2 (Genetic drift) Though to date, only limited alterations seen in the spike protein 20%-40% of total COVID-19 cases are asymptomatic Would need a greater number of trial enrollees as exact incidence rates are unknown Partial efficacy in a young healthy adult does not predict similar effectiveness amount older adults with comorbidities Trial inclusion population requires both younger and older populations